Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update August 15, 2025
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update August 15, 2025
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update August 13, 2025
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease August 13, 2025
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition August 12, 2025
Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity July 31, 2025
